On June 3, 2024, iBio Inc, a biotechnology company incorporated in Delaware and listed on the NYSE American under the symbol IBIO, filed a Form 8-K with the U.S. Securities and Exchange Commission. The report announced the update of iBio's corporate presentation, which is furnished as Exhibit 99.1 to the report. The updated presentation includes forward-looking statements under the safe harbor provisions and outlines the company's strategic shift from a Contract Development and Manufacturing Organization (CDMO) with a focus on COVID-19 vaccine development to a biotech company leveraging machine learning for antibody therapeutics. The presentation highlights iBio's proprietary Machine Learning Antibody Engine, its transition into the metabolic disease space, and the development of a leading biologics company. It...Show More

On June 3, 2024, iBio Inc, a biotechnology company incorporated in Delaware and listed on the NYSE American under the symbol IBIO, filed a Form 8-K with the U.S. Securities and Exchange Commission. The report announced the update of iBio's corporate presentation, which is furnished as Exhibit 99.1 to the report. The updated presentation includes forward-looking statements under the safe harbor provisions and outlines the company's strategic shift from a Contract Development and Manufacturing Organization (CDMO) with a focus on COVID-19 vaccine development to a biotech company leveraging machine learning for antibody therapeutics. The presentation highlights iBio's proprietary Machine Learning Antibody Engine, its transition into the metabolic disease space, and the development of a leading biologics company. It also details the company's patented technology stack designed to address challenges in antibody discovery and development, and its preclinical pipeline targeting hard-to-drug targets in oncology and cardio-metabolic diseases. The company has established partnerships with Eli Lilly, NIH, and others, and has sold a PD-1 asset to Otsuka with potential milestone payments. The presentation also outlines upcoming catalysts for 2024 and 2025, including research agreements and potential partnerships. iBio's leadership team is highlighted, with a focus on their extensive industry experience. Financial highlights indicate that as of May 13, 2024, iBio has approximately $17.9 million in cash and equivalents, with 8,623,676 shares of common stock outstanding as of May 31, 2024. The company has completed the sale of its Texas Manufacturing Facility, eliminating substantial secured debt, and has a financial runway through June 2025.